Sugi Predict

Sugi Predict / Compounds / SCHEMBL3383518

SCHEMBL3383518

SCHEMBL3383518

O=c1[nH]c2ccc(Cl)cc2c(N[C@@H]2CN3CCC2CC3)c1-c1nc2ccccc2[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CHEK1 O14757 17/20 1.00
▸ PRKD3 O94806 3/20 0.73
▸ PRKCG P05129 3/20 0.73
▸ PRKCB P05771 3/20 0.73
▸ PRKCA P17252 3/20 0.73
▸ CCNA2 P20248 3/20 0.73
▸ PRKCH P24723 3/20 0.73
▸ CDK2 P24941 3/20 0.73
▸ PRKCI P41743 3/20 0.73
▸ PRKCE Q02156 3/20 0.73
▸ PRKCQ Q04759 3/20 0.73
▸ PRKCZ Q05513 3/20 0.73
▸ PRKCD Q05655 3/20 0.73
▸ PRKD1 Q15139 3/20 0.73
▸ AURKA O14965 1/20 0.56
▸ PDGFRB P09619 3/20 0.51
▸ FGFR1 P11362 3/20 0.51
▸ KDR P35968 3/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29379375 1.00 CHEK1 (1.00) CHEK1PRKD3PRKCGPRKCBPRKCA
SCHEMBL29387680 1.00 CHEK1 (1.00) CHEK1PRKD3PRKCGPRKCBPRKCA
SCHEMBL15105373 1.00 CHEK1 (1.00) CHEK1PRKD3PRKCGPRKCBPRKCA
SCHEMBL31207550 1.00 CHEK1 (1.00) CHEK1PRKD3PRKCGPRKCBPRKCA
SCHEMBL3384695 1.00 CHEK1 (1.00) CHEK1PRKD3PRKCGPRKCBPRKCA
SCHEMBL14795854 0.94 CHEK1 (0.88) CHEK1PRKD3PRKCGPRKCBPRKCA
SCHEMBL14795716 0.94 CHEK1 (0.88) CHEK1PRKD3PRKCGPRKCBPRKCA
SCHEMBL6393950 0.94 CHEK1 (0.88) CHEK1PRKD3PRKCGPRKCBPRKCA
SCHEMBL14795819 0.93 CHEK1 (0.87) CHEK1PRKD3PRKCGPRKCBPRKCA
SCHEMBL3379844 0.93 CHEK1 (0.87) CHEK1PRKD3PRKCGPRKCBPRKCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 251 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10744141-B2 Compositions and methods for treating cancer CASE WESTERN RESERVE UNIVERSITY (US) 2020-08-18 — — US claimed
US-20180185382-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER CASE WESTERN RESERVE UNIVERSITY 2018-07-05 — — US claimed
EP-3313819-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER Case Western Reserve University (US) 2018-05-02 — — EP claimed
WO-2016210134-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER CASE WESTERN RESERVE UNIVERSITY (US) 2016-12-29 — — WO claimed
US-20160252530-A1 AGENT FOR PREVENTING OR TREATING SPINOCEREBELLAR ATAXIA NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (JP) 2016-09-01 — — US claimed
US-20260076968-A1 AZA-QUINOLINE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2026-03-19 — — US disclosed
US-12570625-B2 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof NOVARTIS AG (CH) 2026-03-10 — — US disclosed
EP-4034535-B1 AZA-QUINOLINE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2026-03-04 — — EP disclosed
US-12544374-B2 AZA-quinoline compounds and uses thereof NOVARTIS AG (CH) 2026-02-10 — — US disclosed
EP-4541381-B1 STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS ADVANCED ACCELERATOR APPLICATIONS S A (FR) 2026-02-04 — — EP disclosed
EP-4541380-B1 STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS ADVANCED ACCELERATOR APPLICATIONS S A (FR) 2025-12-10 — — EP disclosed
EP-4545101-B1 STABLE, CONCENTRATED RADIONUCLIDE COMPLEX SOLUTIONS ADVANCED ACCELERATOR APPLICATIONS S A (FR) 2025-12-10 — — EP disclosed
US-20040006101-A1 Quinolinone derivatives CHIRON CORPORATION 2004-01-08 — — US disclosed
WO-2003087095-A1 QUINOLINONE DERIVATIVES CHIRON CORPORATION (US) 2003-10-23 — — WO disclosed
US-20030158224-A1 Quinolinone derivatives CHIRON CORPORATION 2003-08-21 — — US disclosed
US-6605617-B2 Treating a patient in need of an inhibitor of vascular endothelial growth factor receptor tyrosine kinase CHIRON CORPORATION 2003-08-12 — — US disclosed
EP-1317442-A1 QUINOLINONE DERIVATIVES AS TYROSINE KINASE INHIBITORS CHIRON CORPORATION (US) 2003-06-11 — — EP disclosed
US-20030028018-A1 Quinolinone derivatives CHIRON COPORATION 2003-02-06 — — US disclosed
US-20020107392-A1 Quinolinone derivatives NOVARTIS AG (CH) 2002-08-08 — — US disclosed
WO-2002022598-A1 QUINOLINONE DERIVATIVES AS TYROSINE KINASE INHIBITORS CHIRON CORPORATION (US) 2002-03-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12570625-B2 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof IKZF1, IKZF2, BCL6 CHEK1 2505/4885PRKD3 200/4885PRKCG 625/4885
US-20030028018-A1 Quinolinone derivatives SLCO1B1, SLCO1B3, SLCO1A2 CHEK1 3389/4885PRKD3 4341/4885PRKCG 4656/4885
US-20180185382-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER PPP2CA, PPP3CA, PPP4C CHEK1 178/4885PRKD3 226/4885PRKCG 82/4885
US-20260076968-A1 AZA-QUINOLINE COMPOUNDS AND USES THEREOF EZH2, SUZ12, NR3C1 CHEK1 3282/4885PRKD3 2435/4885PRKCG 2172/4885
US-10744141-B2 Compositions and methods for treating cancer PPP2CA, PPP3CA, PPP4C CHEK1 178/4885PRKD3 226/4885PRKCG 82/4885
US-20030158224-A1 Quinolinone derivatives SLCO1B1, SLCO1B3, SLCO1A2 CHEK1 3389/4885PRKD3 4341/4885PRKCG 4656/4885
US-20020107392-A1 Quinolinone derivatives SLCO1B1, SLCO1B3, SLCO1A2 CHEK1 3389/4885PRKD3 4341/4885PRKCG 4656/4885
US-12544374-B2 AZA-quinoline compounds and uses thereof EZH2, NR3C1, SUZ12 CHEK1 3267/4885PRKD3 2174/4885PRKCG 1219/4885
US-20040006101-A1 Quinolinone derivatives SLCO1B1, SLCO1B3, SLCO1A2 CHEK1 3389/4885PRKD3 4341/4885PRKCG 4656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.